ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
ZSTK3744 was identified through screening for its cell growth-inhibitory activity on chemotherapy-resistant TNBC cells. ZSTK3744 exerts its activity through AhR. ZSTK3744 exhibits superior cell growth-inhibitory activity compared with other AhR agonists and demonstrates a favorable safety profile. Therefore, ZSTK3744 is a promising therapeutic agent for overcoming chemotherapy resistance in TNBC.
Authors
- Shinsuke Hiramoto
- Kotomi Akatsuka
- Takahiro Ohashi (ORCID: https://orcid.org/0000-0002-5262-5294)
- Keiko Fukushima (ORCID: https://orcid.org/0000-0002-5215-4488)
- Mai Todoroki
- Ryuichiro Ohshita
- T. Nagasaki
- Eika Higashi
- Sayuri Terada
- Hisashi Yoshimi
- Yuko Nagata
- Kayoko Kawai-Asami
- Makoto Furuya
- Mizuki Kuramochi
Institutions
- Zenyaku Kogyo (Japan) (JP)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0119
- Primary Topic
- Toxic Organic Pollutants Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00